OncoCell MDx
Corvallis
About OncoCell MDx
OncoCellMDx is a privately held company dedicated to the development and commercialization of novel diagnostic tests utilizing proprietary technologies created at Harvard Medical School. In particular, They have developed a noninvasive blood-based immunogenomic assays that will aid the physician to better understand the underlying pathology. The first product is for assessing the severity of prostate cancer. Other oncology indications as well as non-oncology indications are part of their pipeline.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $22.2M
- Funding stage: Early Stage Venture
- Last round: Series B (Sep 2019)
- Website: oncocellmdx.com
Canonical: https://fsome.com/organization/oncocell-mdx-159668 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.